A61K 9/5047
Cellulose ethers containing no ester groups
Official title: {Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose}
A61K9/5047 (Cellulose ethers containing no ester groups) appears on 907 US grants and 1,523 published applications in this corpus.
Search patents in A61K- Granted patents
- 907
- Published applications
- 1,523
- Assignees
- 569
- Inventors
- 2,295
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 3 | 0 |
| 1977 | 2 | 0 |
| 1978 | 2 | 0 |
| 1979 | 3 | 0 |
| 1980 | 4 | 0 |
| 1981 | 1 | 0 |
| 1982 | 3 | 0 |
| 1983 | 5 | 0 |
| 1984 | 3 | 0 |
| 1985 | 4 | 0 |
| 1986 | 3 | 0 |
| 1987 | 4 | 0 |
| 1988 | 5 | 0 |
| 1989 | 15 | 0 |
| 1990 | 12 | 0 |
| 1991 | 12 | 0 |
| 1992 | 13 | 0 |
| 1993 | 9 | 0 |
| 1994 | 9 | 0 |
| 1995 | 10 | 0 |
| 1996 | 11 | 0 |
| 1997 | 12 | 0 |
| 1998 | 13 | 0 |
| 1999 | 12 | 0 |
| 2000 | 7 | 0 |
| 2001 | 17 | 6 |
| 2002 | 16 | 20 |
| 2003 | 25 | 42 |
| 2004 | 16 | 41 |
| 2005 | 8 | 36 |
| 2006 | 12 | 55 |
| 2007 | 6 | 56 |
| 2008 | 5 | 54 |
| 2009 | 6 | 60 |
| 2010 | 10 | 62 |
| 2011 | 15 | 63 |
| 2012 | 22 | 45 |
| 2013 | 30 | 65 |
| 2014 | 52 | 107 |
| 2015 | 50 | 117 |
| 2016 | 53 | 122 |
| 2017 | 55 | 105 |
| 2018 | 58 | 77 |
| 2019 | 50 | 75 |
| 2020 | 49 | 59 |
| 2021 | 49 | 54 |
| 2022 | 28 | 47 |
| 2023 | 27 | 38 |
| 2024 | 39 | 63 |
| 2025 | 22 | 37 |
| 2026 | 10 | 17 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Prolonged-release pharmaceutical composition for oral administration of sultiame6 Oct 2026US 12,751,928 B2Advicenne
- Delayed-release formulation of duloxetine1 Sep 2026US 12,721,817 B1Almatica Pharma LLC
- Alkaline phosphatase formulations and uses thereof28 Jul 2026US 12,691,077 B2Theriva Biologics, Inc.
- Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative28 Jul 2026US 12,691,090 B2Xwpharma Ltd.
- Modified forms of ambroxol for therapeutic use30 Jun 2026US 12,668,567 B2Zywie Inc.
- Pharmaceutical formulations comprising naltrexone and/or bupropion13 Aug 2026US 2026/0232599 A1Nalpropion Pharmaceuticals LLC
- Pellet of dabigatran etexilate or pharmaceutically acceptable salt thereof6 Aug 2026US 2026/0224545 A1Bostal Drug Delivery Co., Ltd.
- Liquid clonidine extended release composition18 Jun 2026US 2026/0165967 A1Tris Pharma, Inc.
- Escalating dosing regimen for effecting weight loss and treating obesity11 Jun 2026US 2026/0157995 A1Vivus, Inc.
- Pharmaceutical composition comprising high pay load ginger extract granules and process for preparation thereof14 May 2026US 2026/0130964 A1India Glycols Limited
Most cited
By later US patents
- Orally administrable opioid formulations having extended duration of effect437US 5,968,551 APurdue Pharma L. P. · 1999
- Delivery of multiple doses of medications377US 5,837,284 A1998
- Opioid formulations having extended controlled released306US 5,958,459 APurdue Pharma L. P. · 1999
- Sustained release pharmaceutical composition300US 5,378,474 AF. H. Faulding & Co. Limited · 1995
- Sustained release pharmaceutical composition296US 5,202,128 AF. H. Faulding & Co. Limited · 1993